Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4 Methylpyrazole
2. 4 Methylpyrazole Monohydrochloride
3. 4-methylpyrazole
4. 4-methylpyrazole Monohydrochloride
5. Antizol
1. 4-methylpyrazole
2. 4-methyl-1h-pyrazole
3. 7554-65-6
4. Antizol
5. 1h-pyrazole, 4-methyl-
6. 4-methylpyrazol
7. Fomepizol
8. Fomepizolum
9. Fomepizol [inn-spanish]
10. Fomepizolum [inn-latin]
11. Antizol-vet
12. 4-mp
13. 4-methyl Pyrazole
14. Pyrazole, 4-methyl-
15. Chebi:5141
16. Mfcd00005245
17. Nsc-760365
18. 83lcm6l2by
19. Fomepizole [usan:inn]
20. Antizol (tn)
21. Einecs 231-445-0
22. Unii-83lcm6l2by
23. Brn 0105204
24. Fomepizole [usan:inn:ban]
25. 4-methyl-pyrazole
26. Fomepizole, 99%
27. Fomepizole (antizol)
28. 4-methyl-1h_pyrazole
29. Fomepizole [mi]
30. Fomepizole [inn]
31. Fomepizole [jan]
32. Fomepizole [usan]
33. Lopac-m-1387
34. M0774
35. Fomepizole [vandf]
36. Ec 231-445-0
37. Fomepizole [mart.]
38. Chembl1308
39. Fomepizole [who-dd]
40. Lopac0_000723
41. 5-23-05-00031 (beilstein Handbook Reference)
42. Mls001335923
43. Fomepizole (jan/usan/inn)
44. Fomepizole [green Book]
45. Dtxsid3040649
46. Fomepizole [orange Book]
47. Gtpl11705
48. Hms3713h14
49. Hms3868m13
50. Pharmakon1600-01506159
51. Zinc897288
52. Act05848
53. Act08853
54. Albb-016317
55. Hy-b0876
56. Bdbm50226186
57. Cl3422
58. Nsc760365
59. S1717
60. Stk256626
61. Akos000265586
62. Ab00390
63. Ac-4833
64. Ccg-204808
65. Db01213
66. Nsc 760365
67. Sdccgsbi-0050701.p003
68. Ncgc00015646-01
69. Ncgc00015646-02
70. Ncgc00015646-03
71. Ncgc00015646-04
72. Ncgc00015646-10
73. Ncgc00162231-01
74. 615557-09-0
75. Smr000059088
76. Sy006499
77. 4-methyl-1h-pyrazole;4-methylpyrazole
78. Sbi-0050701.p002
79. Db-022514
80. Db-094915
81. A9615
82. Am20100737
83. Bb 0257933
84. Ft-0626518
85. En300-50246
86. C07837
87. D00707
88. Ab00918526_06
89. Ab00918526_07
90. 554m656
91. A855125
92. Q416410
93. Q-101886
94. Z969563038
95. 4pz
| Molecular Weight | 82.10 g/mol |
|---|---|
| Molecular Formula | C4H6N2 |
| XLogP3 | 1.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 0 |
| Exact Mass | 82.053098200 g/mol |
| Monoisotopic Mass | 82.053098200 g/mol |
| Topological Polar Surface Area | 28.7 Ų |
| Heavy Atom Count | 6 |
| Formal Charge | 0 |
| Complexity | 44.8 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Antizol |
| PubMed Health | Fomepizole (Injection) |
| Drug Classes | Toxicology-Antidote Agent |
| Drug Label | Antizol (fomepizole) Injection is a competitive inhibitor of alcohol dehydrogenase.The chemical name of fomepizole is 4-methylpyrazole. It has the molecular formula C4H6N2 and a molecular weight of 82.1. The structural formula is:It is a clear to y... |
| Active Ingredient | Fomepizole |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1.5gm/1.5ml (1gm/ml) |
| Market Status | Prescription |
| Company | Paladin Labs |
| 2 of 4 | |
|---|---|
| Drug Name | Fomepizole |
| Drug Label | Fomepizole Injection is a competitive inhibitor of alcohol dehydrogenase. The chemical name of fomepizole is 4-methylpyrazole. It has the molecular formula C4H6N2 and a molecular weight of 82.1. The structural formula is:It is a clear to yellow liqui... |
| Active Ingredient | Fomepizole |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1.5gm/1.5ml (1gm/ml) |
| Market Status | Prescription |
| Company | Navinta; Mylan Institutional; Luitpold |
| 3 of 4 | |
|---|---|
| Drug Name | Antizol |
| PubMed Health | Fomepizole (Injection) |
| Drug Classes | Toxicology-Antidote Agent |
| Drug Label | Antizol (fomepizole) Injection is a competitive inhibitor of alcohol dehydrogenase.The chemical name of fomepizole is 4-methylpyrazole. It has the molecular formula C4H6N2 and a molecular weight of 82.1. The structural formula is:It is a clear to y... |
| Active Ingredient | Fomepizole |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1.5gm/1.5ml (1gm/ml) |
| Market Status | Prescription |
| Company | Paladin Labs |
| 4 of 4 | |
|---|---|
| Drug Name | Fomepizole |
| Drug Label | Fomepizole Injection is a competitive inhibitor of alcohol dehydrogenase. The chemical name of fomepizole is 4-methylpyrazole. It has the molecular formula C4H6N2 and a molecular weight of 82.1. The structural formula is:It is a clear to yellow liqui... |
| Active Ingredient | Fomepizole |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 1.5gm/1.5ml (1gm/ml) |
| Market Status | Prescription |
| Company | Navinta; Mylan Institutional; Luitpold |
Antizol is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis
Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites. Ethylene glycol is first metabolized to glycoaldehyde which then undergoes further oxidation to glycolate, glyoxylate, and oxalate. Glycolate and oxalate are primarily responsible for metabolic acidosis and renal damage seen in ethylene glycol toxicity. {01}{03} Methanol is first metabolized to formaldehyde and then undergoes subsequent oxidation via formaldehyde dehydrogenase to become formic acid. It is formic acid that is primarily responsible for the metabolic acidosis and visual disturbances that are associated with methanol poisoning.
Antidotes
Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AB - Antidotes
V03AB34 - Fomepizole
Absorption
Rapid and complete
Route of Elimination
In healthy volunteers, only 1-3.5% of the administered dose of Antizol (7-20 mg/kg oral and IV) was excreted unchanged in the urine, indicating that metabolism is the major route of elimination. In humans, the primary metabolite of Antizol is 4-carboxypyrazole (approximately 80-85% of administered dose), which is excreted in the urine. The metabolites of Antizol are excreted renally.
Volume of Distribution
0.6 to 1.02 L/kg
Primarily hepatic. the primary metabolite is 4-carboxypyrazole (approximately 80 to 85% of an administered dose). Minor metabolites include 4-hydroxymethylpyrazole and the N -glucuronide conjugates of 4-carboxypyrazole and 4-hydroxymethylpyrazole.
The plasma half-life of Antizol varies with dose, even in patients with normal renal function, and has not been calculated.
Antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase. Alcohol dehydrogenase catalyzes the oxidation of ethanol to acetaldehyde. Alcohol dehydrogenase also catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
